Browse > Article

Genotoxicity Study of CJ-11555  

박지은 (CJ 제약연구소)
이성학 (CJ 제약연구소)
최재묵 (CJ 제약연구소)
김일환 (CJ 제약연구소)
김덕열 (CJ 제약연구소)
노현정 (CJ 제약연구소)
김택로 (CJ 제약연구소)
김영훈 (CJ 제약연구소)
임지웅 (CJ 제약연구소)
Publication Information
Toxicological Research / v.20, no.2, 2004 , pp. 153-158 More about this Journal
Abstract
To evaluate the genotoxicity of CJ-11555, an anti-cirrhotic agent, the reverse mutation test, chromosomal aberration test and in vivo micronucleus test in rats were performed. In the reverse mutation test, the treatment of CJ-11555 at doses of 33.3, 100, 333, 1000, 3330 and 5000 $\mu\textrm{g}$/plate with and without 89 did not induce mutagenicity in Salmonella typhimurium TA98, TA100, TA1535, TA1537, and Escherichia coli (E. call) WP2uvrA. In chromosomal aberration test, CJ-11555 did not induce structural a chromosomal aberration in Chinese hamster ovary (CHO) cells with and without metabolic activation at all doses. In micronucleus test, CJ-11555 did not induce any statistically significant increases in micronucleated polychromatic erythrocyte (MNPCE) at doses of 500, 1000, and 2000 mg/kg. These results suggest that CJ-11555 might not have a mutagenic potential under the conditions in this study.
Keywords
Genotoxicity; CJ-11555; Anti-cirrhotic agent; Reverse mutation; Chromosomal aberration; Micronucleus.;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Green, M.H.L. and Muriel, W.J. (1976): Mutagen testing using trp reversion in Escherichia coli. Mutation Research, 38, 3-32   DOI   PUBMED
2 Kensler, T.W., Egner, P.A., Wang, J.B., Zhu, Y.R., Zhang, B.C., Qian, G.S., Kuang, S.Y., Gange, S.J., Jacobson, L.P., Munoz, A. and Groopman, J.D. (2002): Stratergies for chemoprevention of liver cancer. Eur. J. Cancer Prev. 2, 58-64
3 Thakur, A.J., Berry, K.J. and Mielke, P.W., Jr. (1985): A FORTRAN program for testing trend and homogeneity in proportions. Computer Programs in Biomedicine, 19, 229-233   DOI   ScienceOn
4 Watternberg, L.W. and Bueding, E. (1986): Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) on carcinogenesis induced by benzo[a]pyren, diethylnitrosamine and uracil mustard. Carchinogenesis, 7, 1379-1381.   DOI   ScienceOn
5 Beers, M.H. and Berkow, R. (1999): The Merck manual of diagnosis and therapy, 17th edition. (Accessed on-line).
6 Klensler, T.W. and Helzlsouer, K.J. (1995): Oltipraz : clinical opportunities for cancer chemoprevention. J. Cell Biochem Suppl. P. 22, 101-107
7 Ansher, S. (1985): The chemotherapy of schistosomiasis. Ann. Rev. Pharmacol., 25, 485-508
8 OECA (1977): OECD guideline for the testing of chemicals, Documents 47e, Genetic Toxicology: In vitro Mammalian Chromosomal Aberration Test, Organization for Economic Cooperation and Development, Paris, France
9 OECA (1977): OECD guideline for the testing of chemicals, Documents 47e, Genetic Toxicology: Mammalian Erythrocyte Micronucleus Test, Organization for Economic Cooperation and Development, Paris, France
10 Wattenberg, L.W. (1985): Chemoprevention of cancer. Cancer Res., 45, 1-8
11 OECA (1977): OECD guideline for the testing of chemicals, Documents 471, Genetic Toxicology: Bacterial Reverse Mutation Test, Organization for Economic Cooperation and Development, Paris, France
12 Kang, K.W., Kim, Y., Cho, M.K., Bae, S.K., Kim, C.W., Lee, M.G. and Kim, S.G. (2002): Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. The FASEB Journal, 16, 1988-1990
13 Ames, B.N., McCann, J. and Yamasaki, E. (1975): Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutation Research, 31, 347-364   DOI   PUBMED